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Abstract
New granule cells are continuously generated in the dentate gyrus of the adult hippocampus. During granule cell
maturation, the mechanisms that differentiate new cells not only describe the degree of cell differentiation, but
also crucially regulate the progression of cell differentiation. Here, we describe a gene, tryptophan 2,3-dioxygenase
(TDO), whose expression distinguishes stem cells from more differentiated cells among the granule cells of the
adult mouse dentate gyrus. The use of markers for proliferation, neural progenitors, and immature and mature
granule cells indicated that TDO was expressed in mature cells and in some immature cells. In mice heterozygous
for the alpha-isoform of calcium/calmodulin-dependent protein kinase II, in which dentate gyrus granule cells fail
to mature normally, TDO immunoreactivity was substantially downregulated in the dentate gyrus granule cells.
Moreover, a 5-bromo-2′-deoxyuridine labeling experiment revealed that new neurons began to express TDO
between 2 and 4 wk after the neurons were generated, when the axons and dendrites of the granule cells devel-
oped and synaptogenesis occurred. These findings indicate that TDO might be required at a late-stage of granule
cell development, such as during axonal and dendritic growth, synaptogenesis and its maturation.
Background
Throughout life, new neurons are continuously gener-
ated in the subgranular zone of the hippocampal dentate
gyrus (DG) and in the anterior subventricular zone of
the lateral ventricles [1-3]. In the adult hippocampus,
neural stem cells/progenitor cells and postmitotic gran-
ule cells are distributed in distinct locations [2-4].
Neural stem cells exist near the border between the
hilus and the DG granule cell layer. Neuroblasts gener-
ated in the subgranular zone migrate radially a short
distance into the granule cell layer and are integrated
into the deepest portion of the granule cell layer, where
they differentiate into granule cells, extending dendrites
and axons and receiving synaptic inputs. During devel-
opment, new granule cells express several marker pro-
teins that depend on the level of cell differentiation
[2,3]. Granule cell progenitors develop in three stages,
namely type 1, 2, and 3 progenitors. Type 1 progenitors
express nestin, glial fibrillary acidic protein (GFAP),
brain lipid-binding protein, and sox2. Type 2 and 3 pro-
genitors express Tbr2, doublecortin (DCX), and polysia-
lic acid-neural cell adhesion molecule (PSA-NCAM).
The latter two markers alsoe x i s ta ta ne a r l ys t a g eo f
postmitotic cell development [2,3]. These molecules play
key roles in the development of granule cells [5], and
may thus be involved in the proliferation of type 1 pro-
genitor cells [6-8]. DCX, a microtubule binding protein,
is transiently expressed during migration and outgrowth
of neuroblast axons and dendrites [9]. Because DCX
bundles and stabilizes microtubules, it may also have a
role in developmental events, such as the reorganization
of microtubules. PSA-NCAM seems to be involved in
structural plasticity, such as cell migration and out-
growth of dendrites and axons [4,10], and its expression
almost completely overlaps with that of DCX [2,3].
Thus, it is important to identify marker proteins and
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cium/calmodulin-dependent protein kinase II (CaM-
KIIa), almost all hippocampal granule cells fail to
mature and remain in an immature state [11]. The
behavioral abnormalities in these mice include a severe
working memory deficit and an exaggerated infradian
rhythm, which are similar to symptoms observed in
patients with schizophrenia, bipolar mood disorder, and
other psychiatric disorders [11]. Transcriptome analysis
of the hippocampus of these mutants revealed signifi-
cant changes in the expression of more than 2000 genes
[11]. Further, among the 20 most downregulated genes
in the CaMKIIa+/- hippocampus, the mRNA expression
level of tryptophan 2,3-dioxygenase (TDO) was only
9.2% that of the control levels [11]. Based on the
maturation failure of the granule cells of CaMKIIa+/-
mice and the higher expression of tdo in the hippocam-
pus compared with several regions of the central ner-
vous system [12], it can be inferred that TDO might be
expressed only after a certain stage of granule cell differ-
entiation in the normal mouse.
TDO is a rate-limiting enzyme for the kynurenine
pathway of tryptophan (Trp) metabolism [13], and Trp
concentrations in the hippocampus of Tdo-/- mice are
20-fold higher than that in control mice [14]. In the hip-
pocampus of Tdo-/- mice, levels of serotonin (5-HT),
which is synthesized from Trp, are 2-fold higher than
that in control mice [14]. In addition, adult neurogenesis
is significantly upregulated in the hippocampus and
anterior subventricular zone in Tdo-/- mice [14]. Taken
together, these findings indicate that TDO might be a
key molecule involved in regulating adult hippocampal
neurogenesis.
In the present study, to further clarify the role of
TDO, we determined the expression pattern of TDO in
the granule cells of adult mouse hippocampus using sin-
gle- and double-immunofluorescence microscopy. We
further examined the onset of TDO expression using
5-bromo-2′-deoxyuridine (BrdU) immunohistochemistry.
Results
TDO expression in granule cells
During the development of granule cells in the adult
hippocampus, granule cell progenitors transiently
express some marker proteins, GFAP for type 1 neural
progenitors and DCX for types 2 and 3 progenitors
[2,3]. Using these established marker proteins, we exam-
ined whether TDO was expressed in the progenitors.
Marked reduction of TDO immunoreactivity in Western
blotting and immunostaining of the hippocampus of
Tdo-/- mice as compared with wild type mice showed
the specificity of TDO immunostaining (Fig. 1).
GFAP immunoreactivity was observed mainly in the
subgranular zone, and was not co-labeled with TDO+
cell bodies (0 of 177 GFAP+ cells, n = 3 mice; Fig. 2A).
GFAP immunoreactivity was also observed in the gran-
ule cell layer. Because astrocytes extend their processes
into the granule cell layer, these GFAP-positive (+) pro-
cesses appeared between TDO+ granule cells (Fig. 2A).
Thus, we concluded that few type 1 progenitors express
TDO.
All progenitors are proliferative and therefore contain
the cell proliferation marker Ki-67, which is a nuclear
protein expressed during all phases of the cell cycle
except G0 [15]. Few Ki-67+/TDO+ granule cells were
o b s e r v e d( 0o f1 0 1K i - 6 7 +c e l l s ,n=3m i c e ;F i g .2 B ) .
The result of the DCX staining suggests that TDO
expression starts at a late developmental stage, such as
at the end stage of type 3 progenitors or immature cells,
and might not be expressed in proliferating progenitors.
We further evaluated the coexpression of TDO in
DCX+ cells. DCX is expressed not only in type 2 and
3 progenitors, but also in immature granule cells in
the adult hippocampus [2,3,9]. The expression of DCX
lasts for up to 4 wk after the generation of granule
cells [9]. Type 2 and 3 progenitors are easily distin-
guished from immature cells in the adult DG by their
distribution; namely progenitors are located in the sub-
granular zone and immature cells are located in the
granule cell layer [4]. In the subgranular zone, the rate
of TDO+ cells among DCX+ cells was low (Fig. 2C,
left image), 10.2 ± 4.34% (mean ± SEM, n = 3 mice).
On the other hand, in the granule cell layer, although
the number of DCX+ cells was quite small, almost all
DCX+ cells expressed TDO, 78.1 ± 6.64% (n = 3 mice;
Fig. 2C, right panel). Thus, these results suggest that
TDO expression gradually increased with the develop-
ment of granule cells.
Immature granule cells can be distinguished from type
3 progenitors by the expression of calretinin and their
location in the deepest granule cell layer [2,3,16]. On
the other hand, mature granule cells express calbindin
and are integrated into the granule cell layer [2,3,17].
Thus, it is capable of distinguishing immature granule
cells from mature granule cells by the expression of the
cell markers calretinin and calbindin. To evaluate the
pattern of TDO expression within postmitotic granule
cells, we performed immunofluorescence double-labeling
for calretinin and calbindin with TDO. Calretinin+/TDO
+ cells were detected in the subgranular zone and in the
deepest granule cell layer (Fig. 3). Almost all calbindin
+/TDO+ cells were distributed in the granule cell layer
(Fig. 3). TDO+ cells comprised 284 of 1629 calretinin+
(17.7 ± 6.33%, n = 4 mice) and 2332 of 2354 calbindin+
cells (99.1 ± 0.787%, n = 4 mice; Fig. 4), suggesting that
some immature granule cells, which might be at the
late-stage of development, and mature cells express
TDO.
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cells, using neuronal and glial cell markers. Almost all
TDO+ cells were stained by Tuj1 antibody, which was
reactive to neuronal class III beta-tubulin, but not by
anti-Olig2, or anti-Iba1 antibodies and not mostly by
anti-GFAP, (Figs. 2A and 5). This data suggest that
TDO was expressed specifically in neurons in the adult
mouse hippocampus under physiological conditions.
In the subgranular zone and hilus, TDO+ cells were
also observed, but these cells had larger cell bodies than
the granule cells (Fig. 6). These TDO+ cells possessed
GABA. Thus, the TDO+ cells in the subgranular zone
and hilus are GABAergic interneurons, such as pyrami-
dal basket cells and mossy cells, which are located in
the hilus or at the border between the granule cell layer
and the hilus [18].
It is well known that the SVZ is one of neurogenic
regions in the mammalian CNS. Next, we addressed if
TDO was expressed in the SVZ. As shown in Fig. 7A
and 7B, we did not detect the immunoreactivity for
TDO in the SVZ of either wild type or Tdo-/- mice.
The TDO-immunoreactive structures in the olfactory
bulb (OB), where neuroblasts derived from the SVZ
migrate and differentiate to granule cells and periglo-
merular cells, were hardly observed, indicating that
TDO may not be expressed in the SVZ-OB system.
H o w e v e r ,i tc a n n o tb ee x c l u d e dt h a tT D Ow o u l db e
below detection level. Furthermore, we examined if
another brain region, cerebellum, that contains granule
cells express TDO. Granule cells in the cerebellum were
immunoreactive for TDO, which is consistent with the
relatively high expression of tdo mRNA in the cerebel-
lum of the mice [12] (Fig. 7C). Further study to investi-
gate the role of TDO in the cerebellum is needed.
These results of TDO expression in the SVZ, the OB,
and the cerebellum seem to be similar to those in the
Allen Brain Atlas http://www.brain-map.org/, a database
of gene expressions by in situ hybridization [19].
Reduced TDO expression in the granule cells of CaMKIIa
+/- mice
The findings described above indicate that TDO is
expressed mainly in mature granule cells. We next
examined the expression of TDO in mature cells using
CaMKIIa+/- mice, in which most of DG granule cells
do not express calbindin, and the electrophysiologic and
morphologic features are strikingly similar to those of
normal immature DG granule cells [11,20]. In the DG
of wild-type littermate mice, TDO were expressed in the
granule cells (Fig. 8A). In contrast, the expression of
Figure 1 Specificity of antibodies for tryptophan 2,3-dioxygenase (TDO) by Western blot (A) and immunofluorescent staining (B). A:
The total protein (20 μg) of the dentate gyrus, extracted from the wild-type (lanes 1 and 3) and Tdo-/- mice (lane 2), was subjected to 4% to
12% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis, and transferred to polyvinylidene difluoride membranes. TDO was
detected as described in the Methods section. Note that a 45-kDa band was detected with the anti-TDO antibody. The positions of molecular
weight markers are shown on the left. Lane 3: negative control without the primary antibody. b-Tubulin is a positive control for the Western
blot. B: The hippocampal sections of wild-type and Tdo-/- mice were stained with anti-TDO antibody. In sections of Tdo-/- mice,
immunofluorescence signals were not detected in granule cells, interneurons (arrowhead), CA1, or CA3 cells, suggesting that the secondary
antibody used in this study bound specifically to the primary antibody (mouse IgG). g, granule cell layer; h, hilus.
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of CaMKIIa+/- mice (Fig. 8A). Importantly, because the
expression level of TDO in the interneurons of the
wild-type hilus was similar to those in CaMKIIa+/-
mice, the decreased expression of TDO may be due to
the lack of mature granule cells in CaMKIIa+/- mice.
We also quantified the expression of tdo mRNA using
real-time PCR. The expression level of TDO in the DG
of CaMKIIa+/- mice was 0.39% of that in the wild-type
DG (Fig. 8B).
Time course analysis with BrdU
To determine when TDO was expressed during the
development of granule cells, we performed BrdU
labeling of granule cells. The rates of double-positive
cells for TDO and BrdU were 4.47 ± 0.775, 13.8 ± 2.65,
and 73.3 ± 2.52% at 1, 2, and 4 wk, respectively, after
BrdU injection (Fig. 9). The number of TDO+/BrdU+
cells at 2 wk was significantly increased compared with
that at 1 wk. TDO expression increased dramatically
after 2 wk of age. Moreover, this result is consistent
with the calretinin and calbindin staining results (Figs. 3
and 4) and a previous report that the appearance of cal-
retinin begins 2 wk after the generation of granule cells
and disappears by 4 wk, whereas granule cells begin to
express calbindin at 4 wk [2,3,16,17]. Thus, these find-
ings indicate that TDO begins to be expressed between
2 and 4 wk after the generation of granule cells.
Figure 2 TDO immunoreactivity in progenitor cells. A: The immunoreactivity of a type I progenitor cell marker, glial fibrillary acidic protein
(GFAP), was rarely observed in TDO-expressing cells. B: Cells double-labeled with Ki67 and TDO were scarcely observed (arrowhead). C: Co-
expression of TDO with doublecortin (DCX). Few DCX-positive (+) cells in the subgranular zone, which comprises type 2 progenitor cells,
contained TDO. In contrast, DCX+ cells that integrated into the granule cell layer, which comprises postmitotic immature neurons, co-expressed
TDO (arrows). g, granule cell layer; h, hilus.
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As described above, the immunohistochemical study
showed that TDO was expressed in a part of immature
granule cells and mature ones. We determined the spa-
tial expression pattern of TDO in the DG. Almost uni-
form TDO immunoreactivity was detected along the
anterior-posterior and dorsal-ventral axes (Fig. 10).
Discussion
In the present study, we examined the spatial and tem-
poral expression pattern of TDO in the granule cells of
adult mouse DG. Using a combination of BrdU labeling
and immunofluorescence staining with a specific anti-
TDO antibody, we demonstrated that TDO expression
began at the late-phase of granule cell development,
around 2 to 4 wk after their generation. The mature
granule cell marker calbindin was strongly co-expressed
with TDO. In addition, in the DG of CaMKIIa+/- mice,
in which granule cells remain immature [11], almost no
TDO immunoreactivity was detected. These findings
indicate that TDO is expressed mainly in mature gran-
ule cells and provide evidence that TDO is useful as a
mature granule cell marker.
TDO expression and development of newborn granule
cells in the hippocampal DG
Adult neurogenesis is currently being intensively stu-
died, in particular in the DG and the anterior
Figure 3 TDO immunoreactivity in immature and mature granule cells. A: Immature granule cells that were calretinin+ contained TDO.
Arrows indicate examples of double labeling of calretinin with TDO. Arrowheads indicate cells labeling for calretinin only. B: Co-labeling of a
mature granule cell marker, calbindin, with TDO. Note that almost all calbindin+ granule cells expressed TDO. Higher magnifications of the
boxed-in areas in the merged images are displayed in the right-hand row. g, granule cell layer; h, hilus; m, molecular layer.
Figure 4 Co-labeling rates of TDO expression in immature
(calretinin+) or mature (calbindin+) granule cells. The cell count
data from Fig. 3 were quantified. Values are given as the means ±
SEM of the analysis based on the results of four mice (total cell
counts: calretinin, n = 1629; calbindin, n = 2354).
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morphogenesis, electrophysiologic properties, and
expression pattern of markers are gradually being eluci-
dated [1-3], the mechanism of hippocampal adult neuro-
genesis remains largely unclear. In addition, the
molecules identified in adult neurogenesis are not only
developmental markers of newly generated neurons, but
also play crucial roles in the development of granule
cells. Thus, to elucidate the mechanism of adult neuro-
genesis, it is important to search for new molecular
markers of developmental events of newborn granule
cells. In the present study, we identified TDO as a novel
Figure 5 Neuronal immunoreactivity of TDO in the dentate gyrus. Immunofluorescent analysis revealed that TDO was expressed in neurons
(Tuj1), but not in oligodendrocytes (Olig2) and microglias (Iba1). Almost all Tuj1+ neurons were immunoreactive for TDO. g, granule cell layer; h, hilus.
Figure 6 Immunoreactivity of TDO in the dentate hilar interneurons. TDO-expressing cells in the dentate hilus contained GABA. Arrowheads
indicate TDO and GABA double-positive cells. g, granule cell layer; h, hilus.
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in the mature granule cells of the dentate gyrus, it does
not seem to play a role in the development of the den-
tate granule cells. In fact, the maturation of granule cells
in the dentate gyrus of Tdo- / -m i c ei sc o m p a r a b l et o
that of the control mice (unpublished results). In con-
trast, we previously have shown the increases in the
numbers of neural stem cells and neural progenitor cells
in the hippocampus of Tdo-/- mice, compared with Tdo
+/+ mice [14]. This effect may be mediated by the
increase in 5-HT. Chronic treatments with antidepres-
sants, such as fluoxetine (FLX), a widely used selective
serotonin reuptake inhibitor, stimulate the adult neuro-
genesis in the hippocampus [21,22]. Additionally, in the
hippocampus of Tdo-/- mice, the level of 5-HT, which
is synthesized from Trp, is 2-fold higher than that in
control mice [14]. In addition, 5-HT is involved in the
adult neurogenesis in the hippocampus [23]. Consider-
ing that the expression of TDO protein can be detected
predominantly in the mature neurons, the rise in 5-HT
may act on the neural stem cells/neural progenitor cells
in Tdo-/- mice, and TDO may function in the mature
granule cells as described below.
Within the central nervous system, TDO is the rate-
limiting enzyme in the kynurenine pathway [13]. In this
pathway, TDO begins to catabolize Trp to produce
kynurenine, the downstream substrate of the pathway,
which produces several neurotoxic and neuroprotective
intermediates [13]. For example, quinolinic acid is exci-
totoxic, whereas kynurenine, kynurenic acid, and
Figure 7 Immunoreactivity of TDO in the SVZ, the olfactory bulb, and the cerebellum. A and B: TDO was not stained in the SVZ (A) and
the olfactory bulb (OB) (B). The immunoreactivities for TDO in wild type and Tdo-/- mice were background level. C: In the cerebellum, the
immunoreactivity for TDO was observed in granule cells and Purkinje cells of wild type mice, but these positive structures disappeared in Tdo-/-
mice. The cytoarchitectural organization of Tdo-/- mice was the same as that of wild type mice. E, external plexiform layer; G, granule cell layer;
Gm, glomerular layer; I, internal plexiform layer; LV, lateral ventricle; Mi, mitral cell layer; Mo, molecular layer; P, Purkinje cell layer; St, striatum; Su,
subependymal zone.
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pus, kynurenine aminotransferase, the enzyme that pro-
duces kynurenic acid, is abundant in both neurons and
astrocytes [24-26]. Furthermore, we demonstrated that
mature DG granule cells strongly express TDO. There-
fore, it is possible to speculate that TDO expressed in
hippocampal mature neurons seems to be beneficial to
protect from excitotoxicity by the synthesis of neuropro-
tective metabolites of the kynurenine pathway, such as
kynurenine and kynurenic acid, which suppress N-
methyl-D-aspartate (NMDA) and a7 nicotinic receptors
in the hippocampus [26-28]. This consumption is
further supported by the notion that the kynurenine,
downstream metabolite of TDO, is capable of inducing
expression of the neuronal survival factor, nerve growth
factor [29-31] and the kynurenic acid is capable of med-
iating suppression of excessive NMDA and a7 nicotinic
receptor activity [27,28]. Further examination of the role
of TDO in neuroprotection is needed.
Several molecular markers and their expression time
course have been identified in hippocampal adult neuro-
genesis: GFAP for type 1 progenitors; DCX and PSA-
NCAM for type 2 and 3 progenitors and immature neu-
rons 1 to 2 wk of age; calretinin for immature neurons
2 to 3 wk of age, when new granule cells send out their
axons to CA3 [32,33]; and calbindin for mature neurons
[2,3]. In the present study, we identified TDO as a new
molecular marker of mature granule cells in the hippo-
campus. A mature granule cell marker, calbindin, is
neuroprotective against glutamate excitotoxicity [34,35].
Calbindin is an EF-hand Ca
2+ binding protein that regu-
lates intracellular Ca
2+ homeostasis [34,35]. The expres-
sion of calbindin begins at 4 wk after granule cell
generation [2,3]. This period correlates with near com-
pletion of the excitatory and inhibitory synapses on
granule cells. On the other hand, TDO is expressed
beginning at 2 to 3 wk after granule cell generation,
when granule cells begin to receive synaptic inputs from
the entorhinal cortex [2,3]. Furthermore, considering the
postulated function of TDO described above, TDO
might also be associated with the acquisition and main-
tenance of granule cell functions, such as synapse for-
mation and maintenance, and neuroprotection.
Usefulness of TDO as a maturation marker of the dentate
granule cells
Calbindin, which is generally used as a mature granule
cell marker, widely and strongly expresses in the hippo-
campal formation, such as CA regions and interneurons.
Thus, in the DNA array or real-time PCR analysis of
whole hippocampus of CaMKIIa+/- mice, calbindin
expression was about 60% of its level in control mice,
whereas the ratio of TDO to its control level was only
10% [36], suggesting that TDO may be more sensitive
Figure 8 Immunoreactivity of TDO in the granule cells of CaMKIIa+/- mice. A: TDO was strongly expressed in the granule cells of wild-type
mice, whereas TDO immunoreactivity was greatly reduced in CaMKIIa+/- mice, whose dentate gyrus (DG) granule cells display the physiologic
and anatomic properties of immature cells. Note that interneurons in the hilus of both wild-type and CaMKIIa+/- mice expressed TDO,
suggesting that the large decrease in TDO expression is specific to the DG granule cells. Higher magnification of the boxed-in area in each low-
power image is displayed at the right of each lower-power image. B: Analysis of tdo expression with Real-time PCR. Total RNA was isolated from
the DG of wild-type and CaMKIIa+/- mice. The expression of tdo mRNA in CaMKIIa+/- mice was significantly reduced to 0.39% of wild-type
mice.
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neurogenesis. Likewise, in our most recent paper that
reported the reversal of hippocampal neuronal matura-
tion by serotonergic antidepressants, FLX, mRNA
expression of tdo in the dentate gyrus of FLX-treated
mice was less than 20% of its level in control mice,
whereas in the case of calbindin the ratio to the control
is 35% [37]. These results also indicate that TDO may
be a useful marker for granule cell maturation, especially
when whole hippocampal sample is used for quantitative
PCR and Western blot analyses.
Implication of TDO on the function of the dentate
granule cell
TDO is closely related to psychiatric disorders, such as
schizophrenia, depression, and bipolar disorder [38-40].
Interestingly, abnormal up-regulation or down-
regulation of the kynurenine pathway has been reported
in patients with psychiatric disorders. For example, in
the neocortex of patients with schizophrenia and bipolar
disorder, kynurenine and kynurenic acid levels are sig-
nificantly increased [39,41]. In contrast, the plasma
levels of both kynurenine and kynurenic acid are signifi-
cantly reduced in depression [40]. In the kynurenine
pathway, kynurenic acid controls sensory gating by regu-
lating the activity of a7 nicotinic and NMDA receptors
[42-45]. Additionally, 5-HT is synthesized from Trp
[13], suggesting that the reduced expression of TDO
may lead to an increase in 5-HT synthesis [14]. Impor-
tantly, we recently reported that FLX treatment, which
increases in the concentration of 5-HT in the brain par-
enchyma, induces “dematuraion” of the dentate granule
cells [37]. TDO may also regulate an array of behaviors
including sensorimotor control, cognition, and mood via
Figure 9 Time-course of the double-labeling of TDO with bromodeoxyuridine (BrdU) in the dentate gyrus (DG) granule cells. A: The
images are representatives of double-labeling of BrdU and TDO at 4 wk after injection of BrdU. Arrowhead indicates the same cell in each line.
g, granule cell layer; h, hilus. B: Changes in co-labeling rates of BrdU with TDO in the DG over a period of 4 wk after injection of BrdU are
shown. Values are given as the means ± SEM of the analysis based on the results of three mice. The asterisk and double asterisk indicate
statistically significant differences: *, p < 0.05; **, p < 0.01 (one-way ANOVA and Scheffé’s post hoc test).
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that TDO may play an important role in the cellular
state and function of the dentate granule cells.
Methods
Animals
For immunohistochemical studies, 8-wk-old male
C57BL/6J mice (4 mice for each time point, control, 1,
2, and 4 wk after BrdU administration; total 16 mice;
Charles River Laboratories International Japan Inc.,
Shiga, Japan) were maintained under a normal light-
dark cycle (12 h light/12 h dark). Animals were injected
intraperitoneally with BrdU (50 mg/kg body weight)
every 24 h over 5 d to label newborn neurons. At 1, 2,
and 4 wk after the last BrdU injection, animals were
deeply anesthetized and transcardially perfused with 4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4.
The brains were dissected, immersed overnight in the
same fixative, and transferred to 30% sucrose in phos-
phate buffered saline (PBS) for at least 3 d for cryopro-
tection. We used CaMKIIa+/- mice obtained from
Jackson Laboratories (Bar Harbor, ME), which were also
utilized in our previous study [11]. Then, heterozygous
mice were crossed with C57BL/6 mice for at least 16
generations. We used heterozygous CaMKIIa knockout
mice, because it is difficult to obtain homozygotes due
to mating problems between heterozygous male and
heterozygous female mice. Tdo-/- mice [14] were also
used to check the specificity of the anti-TDO antibody
[14]. Mice were housed and perfused using the same
methods (for CaMKIIa heterozygous mice, 6 wild-type
and 6 heterozygous mice; for Tdo-/- mice, 6 wild-type
and 5 knockout mice; all 8-wk-old males). The brain
samples were stored at 4°C until use. For Western blot
analysis, three 8-wk-old male wild-type and 3 Tdo-/-
mice were used. All animal experiments were approved
by the Institutional Animal Care and Use Committee of
Fujita Health University, based on Law for the Humane
Treatment and Management of Animals (2005) and
Standards Relating to the Care and Management of
Laboratory Animals and Relief of Pain (2006) or
approved by the Institutional Animal Care and USE
Committee of Osaka University Graduate School of
Medicine. Every effort was made to minimize the num-
ber of animals used.
Antibody characterization
In this study, we used the following antibodies as pri-
mary antibodies: a mouse polyclonal antibody for TDO;
mouse monoclonal antibodies for b-tubulin, GFAP, Ki-
67; rabbit polyclonal antibodies for calretinin, calbindin,
and gamma-aminobutyric acid (GABA); a rat monoclo-
nal antibody for BrdU; and a guinea pig polyclonal anti-
body for DCX.
The molecular weight of TDO is 45 kDa [47,48]. With
the anti-TDO antibody (Abnova, Corp., Taipei, Taiwan:
Lot. Number 08234 WULZ), a 45-kDa band that
appeared to be TDO and an 18-kDa band were observed
Figure 10 Spatial expression of TDO in the dentate gyrus (DG). TDO immunoreactivity was almost uniformly detected along the anterior-
posterior and dorsal-ventral axes. A-E: images of TDO between bregma -0.94 and -3.40. F: schematic representation of sagittal section. The
positions of images A-E are indicated by dotted lines. Arrowheads indicate DG.
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protein from Tdo-/- mice, an 18-kDa band was detected,
suggesting that the secondary antibody labeled an extra
common band. As expected, when the Western blot
analysis was performed without the primary antibodies,
the same band appeared in the negative control (lane 3).
In addition, we determined the specificity of the anti-
TDO antibody in mouse brain tissues. In wild-type
mice, the antibody visualized the granule cells of the
DG, interneurons in the hilus region, CA3, and CA1
neurons (Fig. 1B). On the other hand, in the Tdo-/-
mice, immunoreactivity was not observed in the granule
cell layer, CA3, and CA1. We concluded that anti-TDO
antibody was specifically reactive for TDO protein. Cau-
tion that Lot. Number is important for the specificity of
anti-TDO antibody and thus the specificity of anti-TDO
antibody should be re-examined if the different Lot.
anti-TDO antibody is used.
Mouse monoclonal anti-b-tubulin (clone TUB2.1,
Sigma-Aldrich, St. Louis, MO, T4026) was produced by
immunization with purified rat brain tubulin, and reacts
with human, bovine, rat, mouse, and chick tissue. It
recognizes a 55-kDa protein in Western blot analysis
(manufacturer’s technical information). The specificity
of this antibody was confirmed in a previous study [49].
The rabbit polyclonal anti-GFAP antibody (Sigma-
Aldrich, G3893) was generated against GFAP isolated
from cow spinal cord. The antibody is specific to astro-
cytes and ependymal cells of the central nervous system
(manufacturer’s technical information). The specificity
of this antibody was confirmed in a previous study [50].
The antibody directed against Ki-67 was generated
with recombinant human Ki-67 protein as the immuno-
gen (BD Pharmingen, Franklin Lakes, NJ, 550609). This
antibody recognizes two bands (345 and 395 kDa) on
Western blot analyses of human cells, consistent with
the molecular weights of alternatively spliced Ki67 iso-
forms [51]. The anti-Ki67 antibody labels neuronal pre-
cursor cells and stem cells in the hippocampal DG [52].
A guinea pig polyclonal anti-DCX antibody raised
against a synthetic peptide comprising amino acids 350-
365 of mouse DCX (Chemicon, Temecula, CA, AB5910)
was used in this study. On Western blots, this antibody
recognizes a single 40-kDa band, which corresponds to
the calculated molecular mass of DCX [53]. Staining
obtained with this antibody is identical to that described
for other anti-DCX antibodies [9]. DCX labeling was
prominent in the DG and DCX-labeled cells outside
neurogenic regions of the brain were only rarely
detected [9].
Rabbit polyclonal anti-calretinin antibody (Chemicon,
AB5054) was prepared against a recombinant of the
entire amino acid sequence of rat calretinin. This anti-
body recognizes calretinin in human, rat, and mouse
(manufacturer’s technical information). This antibody
recognizes both calcium-bound and calcium-unbound
conformations of calretinin by Western blot (32 kDa;
manufacturer’s technical information). In addition, the
distribution of calretinin neurons in the hippocampi of
our processed tissue was identical to that in previous
reports [54,55].
Rabbit polyclonal anti-calbindin antibody (Swant, Bel-
linzona, Switzerland, CB 38) was raised against recombi-
nant rat calbindin D-28k, according to information
provided by the manufacturer, and is specific for calbin-
din in Western blot [56]. Immunohistochemical staining
is abolished by preadsorption with calbindin protein
[57], and this antibody labels granule cells in the adult
DG [58].
Rabbit polyclonal GABA antiserum (Sigma-Aldrich,
A2052) was prepared against GABA conjugated to
bovine serum albumin (BSA). This antibody shows posi-
tive binding with GABA, and negative binding with BSA
in a dot blot assay (manufacturer’s technical informa-
tion). The pattern of GABA labeling we observed in the
DG was identical with that described previously [59].
Monoclonal rat anti-BrdU antibody (Abcam, Cam-
bridge, UK, ab6326) reacted to the nuclei of cells that
had incorporated BrdU during S-phase of the cell cycle.
We observed a pattern of staining identical with that
described in previous reports of studies using the rat
antibody [60-62].
Monoclonal rabbit anti-neuronal class III beta-tubulin
(Tuj1) antibody (Covance, Emeryville, CA, MRB-435P)
is highly reactive to neuron specific class III beta-tubu-
lin. This antibody does not identify beta-tubulin of glial
cells (manufacturer’s technical information). We
observed a pattern of staining identical with that
described in previous report using the antibody [63].
Polyclonal rabbit anti-Iba1 antibody (Wako, Osaka,
Japan, 019-19741) is raised against a synthetic peptide
corresponding to C-terminal of Iba1. This antibody is
reactive to microglia and macrophage, but not to neu-
rons and astrocytes (manufacturer’s technical informa-
tion). The immunohistological pattern of Iba1 reactive
cells in the hippocampi of our processed tissue was
identical to that in previous report [64].
Polyclonal rabbit anti-olig2 antibody (IBL, Gunma,
Japan, 18953) is raised against a synthetic peptide of
C-terminal of human olig2. The immunohistological
pattern of olig2 reactive cells in the hippocampi of
our processed tissue was identical to that in previous
report [65].
Western blot analysis
Mice were deeply anesthetized and their brains were
removed and immersed in ice-cold PBS. The hippocam-
pus was dissected out and stored at -80°C until use.
Ohira, et al. Molecular Brain 2010, 3:26
http://www.molecularbrain.com/content/3/1/26
Page 11 of 14Tissues in five volumes of PBS containing 0.1% Triton
X-100, 1 μg/ml leupeptin, 1 μg/ml aprotinin, and 1 mM
phenylmethylsulphonyl fluoride were sheared into small
pieces with a pair of scissors, lysed with microhomogen-
izers, and stored on ice for 5 min. The resulting solu-
tions were centrifuged at 15,000 × g for 30 min at 4°C.
The protein content of the supernatants was determined
by the Lowry method. The supernatants were boiled for
3 min in sodium dodecyl sulfate (SDS) sample buffer
(62.5 mM Tris-HCl, 10% glycerol, 2% SDS, 0.05% bro-
mophenol blue, and 1% 2-mercaptoethanol) and centri-
fuged at 5000 × g for 1 min at 4°C. The supernatants
were stored at -80°C until use.
Aliquots of the supernatants (20 μg total protein) were
loaded on 4% to 12% SDS polyacrylamide gradient gels,
and transferred to polyvinylidene difluoride membranes
(GE Healthcare, Buckinghamshire, England). Membranes
were immersed in 5% skim milk (Morinaga, Tokyo,
Japan) in PBS containing 0.005% Tween-20 (PBST) at
room temperature for 1 h with gentle agitation. They
were incubated at 4°C overnight with anti-TDO anti-
body diluted 1:200 and anti-b-tubulin antibody diluted
1:200 with 5% skim milk solution. Membranes were
washed 3 × 10 min in PBST and incubated with a sec-
ondary antibody conjugated with horseradish peroxidase
(Santa Cruz Biotechnology, Santa Cruz, CA) diluted
1:1000 with 5% skim milk solution at room temperature
for 1 h. Following the 3 × 10 min washes with PBST,
proteins were detected with the enhanced chemilumi-
nescence (ECL System, GE Healthcare) and a cooled
CCD camera Light-Capture (ATTO, Tokyo, Japan).
Histology
Brains were mounted in Tissue-Tek (Miles, Elkhart, IN),
frozen, and cut into 50-μm thick coronal sections using
a microtome (CM1850, Leica Microsystems, Wetzlar,
Germany). Sections were stored in PBS containing
sodium azide (0.05%, w/v) at 4°C until staining.
For immunostaining of TDO, sections were incubated
at 80°C for 30 min in 10 mM citrate buffer, pH 9.0, to
retrieve and enhance their antigenicities and staining
intensities. When double-staining with BrdU was per-
formed, the sections were further incubated at 4°C for
1 0m i ni n0 . 1NH C la n dt h e na t3 7 ° Cf o r3 0m i ni n2
N HCl. Sections were washed for 30 min in PBS, and
then blocked in 0.2 M glycine in PBS at room tempera-
ture for 2 h. After washing in PBS for 1 h, sections were
preincubated with PBS-DB (4% normal donkey serum
[Vector Laboratories, Burlingame, CA] and 1% BSA in
P B S )f o r2ha tr o o mt e m p e r a t u r e .T h es e c t i o n sw e r e
incubated at 4°C for 48 h or at room temperature for 12
h with antibodies. We used the following primary anti-
bodies: mouse polyclonal anti-TDO (1:500); mouse
monoclonal anti-GFAP (1:200) and anti-Ki-67 (1:20); rat
monoclonal anti-BrdU (1:100); rabbit monoclonal anti-
Tuj1 (1:1,000); rabbit polyclonal anti-GABA (1:2,000),
anti-calretinin (1:3,000), anti-calbindin (1:5,000), anti-
Iba1 (1:200), anti-olig2 (1:200); and guinea pig polyclo-
nal anti-DCX (1:1,000). After washing in PBS for 1 h,
the sections were incubated at room temperature for 1
h with the following secondary antibodies: anti-mouse
IgG Alexa 488 (1:200; Molecular Probes, Eugene, OR),
anti-rat IgG Alexa 594 (1:200; Molecular Probes), and
anti-rabbit IgG Alexa 546 (1:200; Molecular Probes).
After washing in PBS for 1 h, the sections were
mounted on glass slides coated with 3-aminopropyl-
triethoxysilane and embedded with Permafluor (Thermo
Shandon, Pittsburgh, PA). We used a confocal micro-
s c o p e( L S M5 1 0M E T A ;Z e i s s ,G ö t t i n g e n ,G e r m a n y )t o
obtain images of the stained sections.
Quantitative RT-PCR
RT-PCR was performed according to our previous study
[11]. Briefly, total RNA was isolated from the DG of 27
to 29-wk-old wild-type mice and CaMKIIa mice. First-
strand cDNA was prepared from 2 μgo fD N a s eI - t r e a -
ted total RNA using SuperScript III reverse transcriptase
(Invitrogen, Carlsbad, CA). The expression of related
genes was quantified using the SYBR green reagent (2×
SYBR Green PCR Master Mix; Qiagen, Valencia, CA)
following the instructions of the manufacturer. Quanti-
tative PCR was performed using DNA Engine Opticon 2
Real-Time PCR Detection System (Bio-Rad, Hercules,
CA) with the following conditions: 15 min at 95°C, then
45 cycles of 15 s at 94°C, 30 s at 60°C, 30 s at 72°C and
1 min at 65°C. b-Actin was amplified from all samples
to normalize expression. The following primers were
used: TDO (1-105), 5′-ATGAGTGGGTGCCCGTTTG
and 5′-GGCTCTGTTTACACCAGTTTGAG; b-actin
(851-962), 5′-AGTGTGACGTTGACATCCGTA and 5′-
GCCAGAGCAGTAATCTCCTTCT. Ct values used
were the means of duplicate replicates.
Quantification
Analysis was performed using a confocal microscope
equipped with a 40× objective (Plan-NEOFLUAR, NA =
0.75, Zeiss) and a pinhole setting that corresponded to
less than 1-μm thickness of the focal plane. To exclude
false positives due to the overlay of signals from differ-
ent cells, randomly selected positive cells were analyzed
by moving through the entire z-axis of each cell. Cells
were counted under the live mode of confocal scanning.
A minimum of 100 BrdU-, calretinin-, GFAP-, DCX-,
and Ki-67-positive cells was examined for co-labeling
with TDO in each animal and at each time point. Data
are presented as the mean percentage of BrdU+ cells
co-labeled with TDO (mean ± SEM). The quantification
of double-positive cells was analyzed with a two-way
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Page 12 of 14ANOVA. If a significant main effect was detected by
ANOVA, a Tukey’s post hoc test was used to determine
the source of the detected significance in the ANOVA.
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